- World Pharma News Home » Published News » Financial
(a free service delivered by FeedBurner)
Alpharma, Inc. (NYSE: ALO), a global specialty pharmaceutical company, confirmed that it received an unsolicited, non-binding proposal from King Pharmaceuticals, Inc. (NYSE: KG) to acquire all of the
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
King Pharmaceuticals, Inc. (NYSE: KG) announced that it has submitted to the Board of Directors of Alpharma Inc. (NYSE: ALO) a proposal to acquire all of the outstanding shares of common stock of Alp
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
In the first six months of 2008, Nycomed’s adjusted EBITDA increased by 4.9% to € 653.7 million compared to € 623.3 million in the first six months of 2007, benefiting from the cost decreasing effect
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Roche and Meda, an international specialty pharmaceutical company based in Solna (Stockholm), Sweden, have signed an agreement for the sale of four Roche pharmaceutical products to Meda. The world wi
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Net sales for the second quarter of 2008 increased 18 percent to $2,823 million, compared to $2,386 million in the second quarter of 2007. Net income for the second quarter of 2008 totaled $539 milli
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
The pharmaceutical company Boehringer Ingelheim continued to post strong growth in local currencies in the first half of 2008 (+9.0%). On account of the strength of the euro against the US dollar and
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
The financial statements of the JSC Grindeks for the first half of the year 2008, submitted to Riga Stock Exchange, certify that the Group of Grindeks has operated successfully during the first six m
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
PLIVA d.d. (ZSE: PLVA-R-A), a subsidiary of Barr Pharmaceuticals, Inc. ("Barr"), today reported financial results for the six month period ended 30 June 2008, prepared in accordance with Internatio
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Nycomed agreed with Bayer Schering Pharma on the sale of the preclinical anti-cancer program. The agreement is part of Nycomed's strategic decision not to further invest in oncology R&D activities.
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
- First-half results for continuing operations led by improving Pharmaceuticals performance ahead of expectations and expansion in Vaccines and Diagnostics
- Net sales rise 11% (+2% in local currenc read more »
Discuss Add this link to... Bury
- Net sales rise 11% (+2% in local currenc read more »
Discuss Add this link to... Bury
